HLscience Co., Ltd. (KOSDAQ:239610)
South Korea · Delayed Price · Currency is KRW 5,300.00
-30.00 (-0.56%)
At close: Sep 11, 2026
HLscience Revenue
HLscience had revenue of 2.50B KRW in the quarter ending June 30, 2026, a decrease of -57.06%. This brings the company's revenue in the last twelve months to 10.44B, down -42.45% year-over-year. In the year 2025, HLscience had annual revenue of 16.71B, down -5.43%.
Revenue (ttm)
10.44B
Revenue Growth
-42.45%
P/S Ratio
2.59
Revenue / Employee
137.36M
Employees
76
Market Cap
26.99B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.71B | -958.46M | -5.43% |
| Dec 31, 2024 | 17.66B | -7.92B | -30.97% |
| Dec 31, 2023 | 25.59B | -27.17B | -51.50% |
| Dec 31, 2022 | 52.76B | -51.62B | -49.45% |
| Dec 31, 2021 | 104.38B | -38.66B | -27.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Korea Arlico Pharm | 195.70B |
| Hurum | 94.89B |
| Korean Drug | 65.39B |
| WooGene B&G | 56.49B |
| Seoul Pharma | 51.08B |
| Eagle Veterinary Technology Co.,Ltd | 44.73B |
| Union Korea Pharm | 25.45B |
| Daesung Microbiological Labs. | 25.20B |